CFTR and cystic fibrosis: Ivacaftor (Vertex pharmaceuticals, Cambridge, Ma), the first approved compound of its kind to stimulate MCC by augmenting CFTR activity leads to dramatic improvement in CF related abnormalities of MCC in both upper and lower airways[6].